Clinical Trials Logo

Clinical Trial Summary

Acute retinal necrosis (ARN) is a rare infectious retinitis which can potentially lead to devastating visual outcomes. ARN is diagnosed on the basis of the clinical appearance and disease course according to the diagnostic criteria proposed by the American Uveitis Society: (1) one or more foci of retinal necrosis with discrete borders in the peripheral retina; (2) rapid progression in the absence of antiviral therapy; (3) circumferential spread; (4) occlusive vasculopathy with arteriolar involvement; and (5) a prominent inflammatory reaction in the vitreous and anterior chambers.

Herpesvirus infection, especially varicella-zoster virus (VZV) and herpes simplex virus (HSV), was presumed to be the pathogenic agent in the pathogenesis of ARN. Medical treatment with systemic antiviral agent had been the base of the therapy of ARN for decades and such treatment usually result in regression of retinitis.

However, the visual outcome of ARN remains poor. The major causes of poor visual prognosis in ARN are retinal detachment and optic nerve or macular involvement by ischemic vasculopathy. Less frequent causes include macular hole formation, macular pucker, or hypotony. Rhegmatogenous retinal detachment may occur in 75 % of the untreated eyes. It may occur weeks to months after the onset of inflammation due to delayed formation of retinal breaks, which result from the combination of necrotic retina and vitreoretinal traction.

Therefore, application of argon laser retinopexy prophylactically posterior to necrotic retina or prophylactic vitrectomy to reduce inflammatory factors and the vitreoretinal traction had been used to protect the healthy area from detachment. However, the results were varied and there is no consensus on the efficacy and indications of those prophylactic procedures. We had applied the prophylactic procedure in our treatment for ARN. We aim to access the efficacy of the treatment strategy of ARN and the correlated factors to the outcomes.


Clinical Trial Description

Between 1995 and 2013, the charts of 20 patients (21 eyes) with a clinical diagnosis of ARN and a complete ophthalmic examination at National Taiwan University Hospital were reviewed. The study was approved by the Ethics Committee and Institutional Review Board of National Taiwan University Hospital.

The clinical data recorded included patient demographics, refractive error, lens status, best corrected visual acuity (BCVA), all treatments and retinal anatomical status. Visual acuities and examination findings were recorded at presentation and subsequent follow-up periods for at least 6 months. The area of retina involved was determined by review of retinal drawings and fundus photos by single reader.

All the patients were admitted for intravenous injection of Acyclovir (30mg/kg/day, in 3 divided doses) for 10-14 days and then shifted to oral Acyclovir (30mg/kg/day) at least for further 10-14 days. Systemic corticosteroid and Aspirin were also given. Prophylactic laser photocoagulation was arranged on normal retina to surround the posterior edge of the active lesions if the media was clear enough to approach. If vitritis persisted without improvement under systemic antiviral agent or retinal detachment was noted, vitrectomy would be performed. Visual acuities and retinal anatomical results were recorded during follow-up after procedures. The visual acuity was converted to logarithm of the minimum angle of resolution (logMAR) values for statistical analysis.

Statistical analysis The continuous values are expressed as means ± standard deviation (SD). The differences among the continuous variables were assessed using the Mann-Whitney U test. Non-continuous variables were analyzed by Fisher's exact test. The level of statistical significance was set at p < 0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02222857
Study type Observational
Source National Taiwan University Hospital
Contact
Status Completed
Phase
Start date August 2014
Completion date August 2014

See also
  Status Clinical Trial Phase
Completed NCT03332758 - Inflammasomes in Cell Death in FTMH, ERM, and RRD
Completed NCT03660384 - Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT04535622 - Efficacy of Exercise Program for Facedown Posture-related Pain After Retinal Surgery N/A
Recruiting NCT05863312 - REtinal Detachment Outcomes Study N/A
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT03046719 - Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal N/A
Recruiting NCT01261533 - Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Phase 1
Terminated NCT02068625 - Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Phase 4
Completed NCT00000140 - The Silicone Study Phase 3
Recruiting NCT05543018 - Effect of Intraocular Tamponade on Visual Perception N/A
Not yet recruiting NCT04518696 - Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment N/A
Completed NCT03321253 - Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification N/A
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Enrolling by invitation NCT05566626 - Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera N/A
Not yet recruiting NCT03631108 - Feasibility Study and Preliminary Application Study on Iris OCTA
Recruiting NCT02201706 - Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye N/A
Completed NCT03218371 - Scleral Self-indentation Chandelier-assisted Peripheral Vitrectomy Under Air Rhegmatogenous Retinal Detachment. N/A
Completed NCT00000154 - Diabetic Retinopathy Vitrectomy Study (DRVS) Phase 3